Differentiation of Progression From Treatment Effects in High-Grade Gliomas: A Clinical Trial With Multimodality MR Imaging

• Conditions: Glioma

• Registration Number: NCT03102203
• Lead Sponsor: Jinling Hospital, China

Brief Summary

To evaluate the efficacy of multi-modality magnetic resonance quantitative parameters in evaluating the treatment effects of high-grade gliomas, and to provide new biomarkers for the establishment of new diagnostic criteria for the identification of true and pseudoprogression of high-grade gliomas.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-06-08
• Status Verified: 2017-03
• Study First Submitted: 2017-03-24
• Study First Submitted QC: 2017-03-30
• Last Update Submitted: 2017-03-30
• Study First Posted: 2017-04-05
• Last Update Posted: 2017-04-05
• Primary Completion: 2018-05
• Study Completion: 2018-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 350

Inclusion Criteria

1. Patients with high-grade gliomas confirmed by pathology and have not been treated with concurrent chemoradiotherapy;
2. Written informed consent is obtained.

Exclusion Criteria

1. Patients not suitable for enhanced MRI scanning of patients;
2. Patients who have not finished follow-up concurrent chemoradiotherapy or MR scanning.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Ktrans	10 months	The volume transfer constant in dynamic contrast-enhanced MR Imaging

Trial Locations

Locations (1)

Jinling Hospital; 🇨🇳 Nanjing, Jiangsu, China